NBIX
Neurocrine Biosciences margins
- Stocks
- Healthcare
- NASDAQ: NBIX
- Margins
For this period, Neurocrine Biosciences reports a gross margin of 98%, an operating margin of 23.6%, an EBITDA margin of 29.8%, and a net margin of 20.9%. The biggest positive change was in net margin, increasing 7 percentage points. The biggest negative change was in gross margin, decreasing 0.5 percentage points.
NBIX margin history
Neurocrine Biosciences's margins averaged 98.28% gross, 22.12% operating, 24.61% EBITDA, and 16.49% net during the last 3 years. Against the three-year averages, operating, EBITDA, and net margins are above their three-year averages and gross margin is below its three-year average.
NBIX margin expansion
Year over year, operating margin expanded by 3.9 percentage points, EBITDA margin by 6.8 percentage points, and net margin by 7 percentage points, while gross margin contracted by 0.5 percentage points.
NBIX Gross margin
Over the last 3 years, Neurocrine Biosciences's gross margin averaged 98.28%. At present, Neurocrine Biosciences's current gross margin is 98%, which is 0.3 percentage points below its three-year average. During this period, gross margin reached a high of 98.6% in Dec 2024 and a low of 97.9% in Dec 2023.
NBIX Operating margin
Looking back over the last 3 years, Neurocrine Biosciences recorded an average operating margin of 22.12%. Neurocrine Biosciences's current operating margin is 23.6% and is 1.5 percentage points above its three-year average. The highest operating margin for Neurocrine Biosciences was 25.8% in Sep 2024, while the lowest was 13.3% in Dec 2023.
NBIX EBITDA margin
Across the last 3 years, Neurocrine Biosciences's EBITDA margin averaged 24.61%. As of the latest period, Neurocrine Biosciences's current EBITDA margin is 29.8%, which is 5.2 percentage points above its three-year average. EBITDA margin was highest at 31.9% in Mar 2026 and lowest at 18.7% in Dec 2023.
NBIX Net margin
Over the last 3 years, Neurocrine Biosciences's net margin averaged 16.49%. As of the latest period, Neurocrine Biosciences's current net margin is 20.9%, which is 4.4 percentage points above its three-year average. During this period, net margin reached a high of 21.6% in Mar 2026 and a low of 12.7% in Mar 2025.
NBIX margin group comparison
Neurocrine Biosciences's gross margin of 98% is above the Healthcare sector, the industry and its peers average. Compared to its Healthcare sector average of 68.3%, Neurocrine Biosciences's gross margin is 43% higher.
NBIX margin peer comparison
Frequently asked questions
What is Neurocrine Biosciences's gross margin?
As of Jun 30, 2026, NBIX has a gross margin of 98%.
What is Neurocrine Biosciences's operating margin?
As of Jun 30, 2026, NBIX has an operating margin of 23.6%.
What is Neurocrine Biosciences's EBITDA margin?
The current EBITDA margin for NBIX is 29.8% as of Jun 30, 2026.
What is Neurocrine Biosciences's net margin?
The current net margin for NBIX is 20.9% as of Jun 30, 2026.
What are the average margins of NBIX?
Over the last 3 years, Neurocrine Biosciences's margins averaged 98.3% gross, 22.1% operating, 24.6% EBITDA, and 16.5% net.
What are the highest historical margins of NBIX?
Looking back across 5 years, NBIX reached 98.7% gross in Mar 2022, 25.8% operating in Sep 2024, 31.9% EBITDA in Mar 2026, and 21.6% net in Mar 2026.
What are the lowest historical margins of NBIX?
Within the 5-year period, NBIX recorded its lowest margins at 97.8% gross in Sep 2023, 5.1% operating in Jun 2022, 3.5% EBITDA in Jun 2022, and 0.9% net in Jun 2022.